Myfortic (Mycophenolic Acid)

Mycophenolic acid, the active ingredient in Myfortic, is an immunosuppressant presented as a tablet for oral use. It works by selectively inhibiting lymphocyte proliferation, thereby helping to prevent organ transplant rejection in kidney, heart and liver transplant recipients, and is used as part of a maintenance immunosuppression regimen.

GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and procurement teams worldwide, with capabilities for bulk and kit packaging, regulatory support and reliable cold‑chain logistics where required.

Myfortic is used in transplant medicine to suppress immune‑mediated graft rejection. Kidney transplant: prevents rejection and supports graft survival. Heart transplant: maintains immunosuppression to reduce rejection risk. Liver transplant: helps maintain graft function by suppressing the immune response.

Myfortic may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may affect hydration. - Headache: transient cranial discomfort. - Tremor: fine shaking of the hands.

Serious or Rare Side Effects: - Severe infections: opportunistic infections requiring medical attention. - Leukopenia or neutropenia: reduced white blood cell counts increasing infection risk. - Hepatotoxicity: elevated liver enzymes indicating liver injury.

Patients receiving Myfortic should follow specific safety measures. Monitor blood counts: regular CBC testing to detect leukopenia. Monitor liver function: periodic LFTs to identify hepatotoxicity. Avoid live vaccines: increased risk of vaccine‑derived infection. Adjust dose in renal impairment: dose may need reduction based on kidney function. Counsel on infection signs: educate patients to report fever or unusual symptoms promptly. Store at room temperature: keep in the original pack, protect from moisture.

Myfortic interacts with several medicines; awareness helps avoid complications.

Major Interactions (Avoid): - Cyclosporine: increases mycophenolic acid exposure; concurrent use requires dose adjustment. - Antacids containing aluminum or magnesium: reduce absorption; avoid co‑administration.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone marrow suppression; monitor blood counts. - Rifampin: decreases mycophenolic acid levels; may require dose increase. - Live vaccines: heightened infection risk; avoid during therapy.